Officer STOCK OPTION AWARD granted under Appendix B to the Oxford Immunotec Global PLCOfficer Stock Option Award • March 6th, 2014 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
Contract Type FiledMarch 6th, 2014 Company IndustryThis agreement (this “Agreement”) evidences a stock option granted by Oxford Immunotec Global PLC (the “Company”) to the undersigned (the “Optionee”) pursuant to the Company’s 2013 Share Incentive Plan and Appendix B thereto (together, as amended from time to time, the “Plan”).
Form of Officer STOCK OPTION AWARDOfficer Stock Option Award • February 27th, 2018 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
Contract Type FiledFebruary 27th, 2018 Company IndustryThis agreement (this “Agreement”) evidences a stock option granted by Oxford Immunotec Global PLC (the “Company”) to the undersigned (the “Optionee”) pursuant to the Company’s 2013 Share Incentive Plan and Appendix D thereto (together, as amended from time to time, the “Plan”).
FIRST AMENDMENT TO OFFICER STOCK OPTION AWARDOfficer Stock Option Award • January 2nd, 2015 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
Contract Type FiledJanuary 2nd, 2015 Company IndustryThis First Amendment to Officer Stock Option Award (“Option Amendment”) is made this __ day of December, 2014, by and between Oxford Immunotec Global PLC (the “Company”) and Peter Wrighton-Smith, Ph.D. (“Optionee”).